Fully automated system producing unidose nasal spray devices
for Naloxone, the life-saving opioid overdose drug.
Mount Vernon, NY – TurboFil Packaging Machines LLC, an equipment specialist dedicated solely to the design and development of liquid filling and assembly machines, is collaborating with Bridgewater, NJ-based Amneal Pharmaceuticals to develop an advanced automated assembly and vial filling machine for unidose liquid nasal devices. TurboFil’s state-of-the-art system will be utilized by Amneal to produce naloxone doses, the life-saving drug used to counteract opioid overdoses.
Earlier this year, the U.S. Food and Drug Administration (FDA) approved the over-the-counter sale of naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency.
TurboFil’s system features advanced inspection capabilities to ensure each device performs its critical, time-sensitive mission. The machine's precise and flexible design includes state-of-the-art technology to meet or exceed required accuracy tolerances. The machine combines classical mechanics with modern technology to assemble these devices with precision.
“We are excited to work with TurboFil on this project. Their advanced technology and expertise will help us advance our production capabilities and expand access to this crucial medication,” said Jiten Parikh, Senior Vice President of Operations for Amneal Pharmaceuticals.
“Intranasal administration devices are among the fastest-growing forms of drug delivery, and we’re proud to work with Amneal in their mission to expand availability of a drug on the forefront of the urgent fight against opioid-related deaths,” said Deborah Smook, VP of Marketing & Business Development for TurboFil Packaging Machines LLC.
About TurboFil Packaging Machines LLC
TurboFil is an equipment specialist dedicated solely to the design and development of liquid filling and assembly machines for the pharmaceutical, medical device, health & beauty and chemical industries. Since its inception in 1999, the company has created novel, durable production solutions for some of the industry's most challenging applications, consistently setting new benchmarks for filling precision and operational simplicity.
TurboFil's equipment portfolio features a broad range of standardized equipment, and the company also frequently collaborates with customers to develop, design and construct customized, built-to-spec machines. This versatility has made TurboFil a leader in supplying reliable, efficient and cost-effective filling and assembly systems that fit seamlessly into existing operations. For more information, visit www.TurboFil.com.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceutical products, primarily within the United States.
In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.
